Style | Citing Format |
---|---|
MLA | Abolghasemi R, et al.. "Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration." Cell and Tissue Banking, vol. 23, no. 4, 2022, pp. 767-789. |
APA | Abolghasemi R, Ebrahimibarough S, Mohamadnia A, Ai J (2022). Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration. Cell and Tissue Banking, 23(4), 767-789. |
Chicago | Abolghasemi R, Ebrahimibarough S, Mohamadnia A, Ai J. "Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration." Cell and Tissue Banking 23, no. 4 (2022): 767-789. |
Harvard | Abolghasemi R et al. (2022) 'Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration', Cell and Tissue Banking, 23(4), pp. 767-789. |
Vancouver | Abolghasemi R, Ebrahimibarough S, Mohamadnia A, Ai J. Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration. Cell and Tissue Banking. 2022;23(4):767-789. |
BibTex | @article{ author = {Abolghasemi R and Ebrahimibarough S and Mohamadnia A and Ai J}, title = {Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration}, journal = {Cell and Tissue Banking}, volume = {23}, number = {4}, pages = {767-789}, year = {2022} } |
RIS | TY - JOUR AU - Abolghasemi R AU - Ebrahimibarough S AU - Mohamadnia A AU - Ai J TI - Synergistic Inhibitory Effect of Human Umbilical Cord Matrix Mesenchymal Stem Cells-Conditioned Medium and Atorvastatin on Mcf7 Cancer Cells Viability and Migration JO - Cell and Tissue Banking VL - 23 IS - 4 SP - 767 EP - 789 PY - 2022 ER - |